Pirfenidone
- Generic Name
- Pirfenidone
- Brand Names
- Esbriet, Pirfenidone axunio (previously Pirfenidone AET), Pirfenidone Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C12H11NO
- CAS Number
- 53179-13-8
- Unique Ingredient Identifier
- D7NLD2JX7U
- Background
Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate tumor necro...
- Indication
Pirfenidone is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). In Canada and Europe, it is approved in adults only.
- Associated Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Mild Idiopathic Pulmonary Fibrosis, Moderate Idiopathic Pulmonary Fibrosis
- Associated Therapies
- -
Real-life-persistence to Antifibrotic Treatments
- Conditions
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 800
- Registration Number
- NCT06485635
- Locations
- 🇫🇷
Clinityx, Boulogne-Billancourt, France
Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
- Conditions
- To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal CarcinomaTo Evaluate Whether Pirfenidone Can Reshape the Tumor Microenvironment in Colorectal CancerCombination of Fruquintinib and Anti-PD-1 Antibody Was Reported to Improve Patient Prognosis in Colorectal Cancer
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 25
- Registration Number
- NCT06484153
Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 60
- Registration Number
- NCT06253117
- Locations
- 🇺🇸
UAB, Birmingham, Alabama, United States
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
- Conditions
- Interventions
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT06241560
- Locations
- 🇬🇪
LTD The First Medical Center, Tbilisi, Georgia
🇬🇪LTD "Aversi clinic", Tbilisi, Georgia
Perfenidone in Type 2 Diabetic Patients With Diabetic Neuropathy
- Conditions
- Interventions
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Sidrah Lodhi
- Target Recruit Count
- 60
- Registration Number
- NCT06224790
- Locations
- 🇵🇰
King Edward Medical University, Lahore, Punjab, Pakistan
Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 66
- Registration Number
- NCT06142318
- Locations
- 🇨🇳
Fujian Provinical Hospital, Fuzhou, China
🇨🇳Jieyang people's hospital, Jieyang, China
🇨🇳Huizhou Central People's Hospital, Huizhou, China
A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 14
- Registration Number
- NCT06070610
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Biomarkers in HF: Circulating Biomarkers of Fibrosis and Cardiovascular Disease
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Manchester University NHS Foundation Trust
- Target Recruit Count
- 107
- Registration Number
- NCT05826821
- Locations
- 🇬🇧
Manchester University NHS Foundation Trust, Manchester, United Kingdom
Pifenidone Prophylactic Therapy for Radiation Lung Injury in Patients Who Have Previously Received Immune Checkpoint Inhibitors
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Hubei Cancer Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT05801133
- Locations
- 🇨🇳
Hubei Cancer Hospital, Wuhan, Hubei, China
Dose Reduction and Discontinuation With Anti-Fibrotic Medications
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2778
- Registration Number
- NCT05779007
- Locations
- 🇺🇸
Boehringer Ingelheim, Ridgefield, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.